Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 188 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Diseases of the Skin and Subcutaneous Tissue Clear all

Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

NCT04888585

View directory record Official record

Conditions: Rheumatoid Arthritis (RA)
Interventions: ABBV-154, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 101
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more

Source: ClinicalTrials.gov public record

Updated Oct 7, 2024 · Synced May 21, 2026, 5:36 PM EDT

Recruiting Phase 3 Interventional

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

NCT06679270

View directory record Official record

Conditions: Familial Partial Lipodystrophy
Interventions: Metreleptin; Drug
Lead sponsor: Amryt Pharma; Industry
Eligibility: 13 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Birmingham, Alabama • Boca Raton, Florida • Boston, Massachusetts + 4 more

Source: ClinicalTrials.gov public record

Updated Feb 1, 2026 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

NCT06444451

View directory record Official record

Conditions: Alopecia Areata
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older

Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 14 more

Source: ClinicalTrials.gov public record

Updated Oct 23, 2025 · Synced May 21, 2026, 5:36 PM EDT

Terminated Phase 3 Interventional Results available

Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis

NCT01127893

View directory record Official record

Conditions: Osteoarthritis
Interventions: Tanezumab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: La Mesa, California

Source: ClinicalTrials.gov public record

Updated Mar 9, 2021 · Synced May 21, 2026, 5:36 PM EDT

Completed Not applicable Interventional Accepts healthy volunteers

Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus

NCT00133107

View directory record Official record

Conditions: Lichen Planus, Oral
Interventions: efalizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older

Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: St Louis, Missouri

Source: ClinicalTrials.gov public record

Updated Aug 18, 2011 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Belimumab Administered Subcutaneously to Healthy Subjects

NCT01583530

View directory record Official record

Conditions: Healthy
Interventions: Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg, Single Dose Group: Belimumab SC 1 x 200 mg, Multiple Dose Group: Belimumab SC 2 x 120 mg weekly, Multiple Dose Group: Belimumab SC 1 x 200 mg weekly; Biological
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 4
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more

Source: ClinicalTrials.gov public record

Updated Aug 6, 2013 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting Phase 3 Interventional

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

NCT06768671

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 12 Years to 17 Years

Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Stanford, California • Washington D.C., District of Columbia + 14 more

Source: ClinicalTrials.gov public record

Updated May 5, 2026 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934

View directory record Official record

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older

Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 82
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more

Source: ClinicalTrials.gov public record

Updated Apr 19, 2026 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 1 Interventional

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

NCT01362153

View directory record Official record

Conditions: Rheumatoid Arthritis
Interventions: Golimumab; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Glendale, Arizona • Aventura, Florida • Palm Harbor, Florida + 6 more

Source: ClinicalTrials.gov public record

Updated Oct 1, 2017 · Synced May 21, 2026, 5:36 PM EDT

Terminated Phase 2 Interventional

Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06118099

View directory record Official record

Conditions: Hidradenitis
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: Phoenix, Arizona • Fremont, California • Margate, Florida + 9 more

Source: ClinicalTrials.gov public record

Updated Feb 3, 2026 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 3 Interventional Results available

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

NCT01636687

View directory record Official record

Conditions: Plaque-type Psoriasis
Interventions: Placebo, Secukinumab 150mg, Secukinumab 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more

Source: ClinicalTrials.gov public record

Updated Sep 26, 2018 · Synced May 21, 2026, 5:36 PM EDT

Completed Not applicable Interventional

Pre-pectoral AlloDerm® to Reinforce Tissues in Tissue Expander Breast Reconstruction

NCT03195322

View directory record Official record

Conditions: Postoperative Pain, Postoperative Nausea and Vomiting, Quality of Life, Breast Cancer, Breast Prosthesis; Pain
Interventions: Pre-pectoral Tissue Expander; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Dec 15, 2021 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 1 Interventional Results available

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

NCT04803305

View directory record Official record

Conditions: Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia
Interventions: PF-06946860, Placebo for PF-06946860; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 32
States / cities: Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more

Source: ClinicalTrials.gov public record

Updated Jan 11, 2024 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 3 Interventional Results available

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

NCT04656418

View directory record Official record

Conditions: Hereditary Angioedema
Interventions: CSL312, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older

Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more

Source: ClinicalTrials.gov public record

Updated Jun 28, 2023 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475

View directory record Official record

Conditions: Psoriasis
Interventions: Risankizumab, Apremilast; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 26
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more

Source: ClinicalTrials.gov public record

Updated Apr 29, 2024 · Synced May 21, 2026, 5:36 PM EDT

Enrolling by invitation Phase 3 Interventional

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637

View directory record Official record

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 12 Years and older

Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 49
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 40 more

Source: ClinicalTrials.gov public record

Updated May 5, 2026 · Synced May 21, 2026, 5:36 PM EDT

Terminated Phase 2 Interventional Results available

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

NCT01217814

View directory record Official record

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Placebo, Golimumab, methotrexate (MTX), Folic/folinic acid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more

Source: ClinicalTrials.gov public record

Updated Aug 31, 2017 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 3 Interventional Results available

Study of Secukinumab With 2 mL Pre-filled Syringes

NCT02748863

View directory record Official record

Conditions: Psoriasis
Interventions: Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more

Source: ClinicalTrials.gov public record

Updated Jul 14, 2019 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 3 Interventional Results available

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

NCT01196091

View directory record Official record

Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions: LY2127399, Placebo every 2 weeks, Placebo every 4 weeks, Standard of Care; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 88
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 85 more

Source: ClinicalTrials.gov public record

Updated Jun 11, 2018 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 1Phase 2 Interventional

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

NCT01009242

View directory record Official record

Conditions: Arthritis, Rheumatoid Arthritis
Interventions: CDP6038, Placebo IV, Placebo SC, CDP 6038 SC, Methotrexate; Biological · Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Duncansville, Pennsylvania • Dallas, Texas • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Nov 14, 2024 · Synced May 21, 2026, 5:36 PM EDT

Completed Not applicable Interventional

Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis

NCT00972062

View directory record Official record

Conditions: Multiple Sclerosis
Interventions: Bach's Rescue Remedy Cream, Placebo Cream; Other
Lead sponsor: University of North Carolina, Charlotte; Other
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charlotte, North Carolina

Source: ClinicalTrials.gov public record

Updated Mar 6, 2012 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 2 Interventional

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

NCT06015308

View directory record Official record

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Tdap vaccine, PPS vaccine; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older

Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 2 Interventional Results available

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

NCT04015518

View directory record Official record

Conditions: Palmoplantar Pustulosis (PPP)
Interventions: Spesolimab, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • Beverly Hills, California • San Diego, California + 11 more

Source: ClinicalTrials.gov public record

Updated Oct 15, 2025 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 3 Interventional Results available

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT02584959

View directory record Official record

Conditions: Hereditary Angioedema (HAE)
Interventions: C1 esterase inhibitor [human] liquid, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older

Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more

Source: ClinicalTrials.gov public record

Updated Jun 7, 2021 · Synced May 21, 2026, 5:36 PM EDT